Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals in Improvement of Stress and Fatigue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01100632
Recruitment Status : Suspended
First Posted : April 9, 2010
Last Update Posted : October 27, 2010
Information provided by:
Azidus Brasil

Brief Summary:
We hope that with the drug, patients obtain reduced levels of stress and fatigue, according to the scales that we use in the study. Hopefully the results of the treated group are significantly higher than the control group (placebo).

Condition or disease Intervention/treatment Phase
Reduction of Stress and Fatigue Dietary Supplement: Ginseng, vitamins, minerals Other: Placebo - Gelatin capsule Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : September 2010
Estimated Primary Completion Date : November 2010
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue Minerals
Drug Information available for: Ginseng
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment
Treatment with the combination of Panax ginseng, vitamins and minerals
Dietary Supplement: Ginseng, vitamins, minerals
2 capsules per day
Placebo Comparator: Placebo
Other: Placebo - Gelatin capsule
2 capsules per day

Primary Outcome Measures :
  1. Reduction of stress and fatigue [ Time Frame: 14 and 28 days ]
    1. Stress: ISS Scale will be assessed by the scale - Inventory of Symptoms of Stress in the time selection / screening, 14 and 28 days ± 2 days of treatment.
    2. Fatigue: FSS Scale will be assessed by the scale - Fatigue Severity Scale Selection in The Times / Triage, 14 and 28 days ± 2 days of treatment.

Secondary Outcome Measures :
  1. Quality of life and Sexual Function [ Time Frame: 14 and 28 days ]

    c) Quality of life: the quality of life of patients will be assessed using the Short Form 36 questionnaire (SF-36) during the period included 14 and 28 days ± 2 days of treatment.

    d) Sexual function: evaluation of possible changes in libido or sexual performance that this drug will develop will be made by direct questioning by the doctor to the patient inclusion period 14 and 28 days ± 2 days of treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Agree with all study procedures, signing the IC in two ways;
  • Patients older than 18 years, male or female, regardless of ethnicity or social class;
  • Presence of mild to moderate stress, confirmed with the Stress Symptom Inventory (ISS);
  • Presence of staff fatigue with a score greater than 36 according to the Fatigue Severity Scale (FSS).

Exclusion Criteria:

Constitute exclusion criteria of the study:

  • Participation in clinical trials in the 12 months preceding the survey;
  • Current treatment with drugs that are stimulants or central nervous system depressants such as hypnotics, anxiolytics, antipsychotics, antidepressants, statins and muscle relaxants;
  • Alternative therapies that scientifically, or have no influence in the tables of stress or fatigue as color therapy, acupuncture or relaxing massages;
  • Treatment psychotherapeutic medication or not;
  • Current treatment or prediction of treatment with oral anticoagulants (due to interaction with the tocopherol);
  • Women who are pregnant or lactating;
  • Patients with lactose intolerance;
  • Patients allergic to soy or peanuts;
  • chronic renal failure;
  • Patients using other multivitamins or individual vitamins such as vitamin D and / or A.
  • Chronic alcoholism;
  • Patients with clinical diagnosis of diseases causing severe chronic pain or adversely affect the clinical interpretation as fibromyalgia, multiple sclerosis, neuropathies and myopathies;
  • Patients with hypothyroidism or hyperthyreosis diagnosed clinically;
  • Patient history and physical examination suggestive of severe hepatorenal failure;
  • Patients with decompensated diabetes mellitus (fasting glucose above 180 mg / dL);
  • Patients undergoing treatment for cancer;
  • Amendment of the routine of life during the study as early vacation or suspected change in working hours;
  • Patients with complaints of excessive sleepiness caused by organic disease such as sleep apnea and morbid obesity (BMI above 35);
  • History of hypersensitivity to any component of the product under investigation;
  • Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study.

Responsible Party: Alexandre Frederico, LAL Clinica Pesquisa e Desenvolvimento Ltda Identifier: NCT01100632     History of Changes
Other Study ID Numbers: GEREMS0310
Version 01 - March 11, 2010
First Posted: April 9, 2010    Key Record Dates
Last Update Posted: October 27, 2010
Last Verified: April 2010

Additional relevant MeSH terms:
Signs and Symptoms
Growth Substances
Physiological Effects of Drugs